It stands for Acute coronary syndrome (ACS) which is a general term for a range of conditions that occur when there is a sudden reduction of blood flow to the heart, such as ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).1
It is estimated, more than 7 Million people are diagnosed with ACS each year.2
30% of patients do not experience any chest pain3 which can contribute to erroneously discharging patients.4
Emergency departments worldwide continually face the challenge of rapidly diagnosing and triaging chest pain patients.
Patient test results can help clarify the clinical picture. Timely action on cardiac laboratory results is critical and may improve patient outcomes.
The laboratory can help address some challenges by offering cardiac tests that are accurate, reliable and fast.
The enhanced sensitivity and precision of high sensitivity troponin assays combined with sex-specific cut-offs, allow for faster and more accurate assessment of suspected myocardial infarction,7 particularly in women, who tend to have lower circulating levels of troponin, even when having an MI. 5
Alinity and ARCHITECT High Sensitive Troponin-I results may enable easier management of patients with suspect
Acute Myocardial Infarction (AMI) through:
This assay complies with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) requisites for high sensitive troponin analytical characteristics, including low end detection in a normal healthy population and imprecision of less than 6% CV at the medical decision points, which help to provide accurate and reliable results for ACS evaluation.
The use of sex-specific cutoffs enables more tailored healthcare and facilitates effective and efficient identification of those with clinically significant increases in their circulating troponin-I levels. When sex-specific cut-offs are not employed, women are potentially 6-times more likely to experience a recurrent MI or cardiovascular death.5
A "true" high sensitive assay for cardiac troponin I allows a reduction in the testing interval of patients admitted for suspect AMI from 6 hours to 3 hours or even down to 1 hour, as advocated by the most recent European Society of Cardiology (ESC) guidelines.6
Abbott instruments help to increase operational productivity and consistently provide high quality services, managing increased work volumes and operating with fewer trained personnel.
As an aid in the diagnosis of myocardial infarction.
To aid in the assessment of 30-day and 90-day prognosis relative to all-cause mortality and major adverse cardiac events consisting of MI, revascularisation and cardiac death in patients who present with symptoms suggestive of ACS.
In conjunction with clinical and diagnostic findings, it aids in categorizing asymptomatic individuals at risk of cardiovascular disease, including cardiovascular death, myocardial infarction, coronary revascularisation, heart failure or ischemic stroke.
Abbott's high-quality immunoassay menu helps laboratories meet requirements to be timely and precise with results.
Learn how Abbott has helped physicians evaluate suspected mild traumatic brain injury (mTBI).
Discover how Alinity uses powerful technology to help redefine and improve operational productivity and confidence in your laboratory.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
